LGND Ligand Pharmaceuticals, Inc.
$296.94 -3.20%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-3.20%
YTD
+62.10%
P/E
30.84
P/B
3.66
ROE
20.1%
Div yield
—
Beta
0.77
Market cap
$6.1B
RSI (14)
51
Next earnings
Nov 4, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$309.41
Close
$296.94
VWAP (n/a)
—
Day high
$309.41
Day low
$293.73
Volume
164K
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?
Yahoo Finance · Sep 29
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal
Yahoo Finance · Sep 29
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?
Yahoo Finance · Sep 29
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
Yahoo Finance · Sep 22
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Yahoo Finance · Sep 22
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
Yahoo Finance · Sep 22
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Sep 24, 2026 View → 8-K Sep 22, 2026 View → 10-Q Aug 7, 2026 View → 8-K Aug 6, 2026 View → 8-K Jul 14, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell LGND. Try it in the Lab to size a position and see the risk.